Defining and measuring negative symptoms of schizophrenia in clinical trials

@article{Marder2014DefiningAM,
  title={Defining and measuring negative symptoms of schizophrenia in clinical trials},
  author={Stephen R. Marder and Brian Kirkpatrick},
  journal={European Neuropsychopharmacology},
  year={2014},
  volume={24},
  pages={737-743}
}

Tables from this paper

Treating Negative Symptoms in Schizophrenia: an Update
TLDR
From this perspective, identification of biomarkers and/or endophenotypes permitting earlier diagnosis and intervention may serve to improve treatment efficacy as well as outcomes.
Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options
TLDR
The lack of clearly efficacious pharmacological treatments for the management of negative symptoms represents a significant unmet need, especially considering the importance of these symptoms on patient outcomes, and further research to identify and characterize novel pharmacology treatments is greatly needed.
Negative Symptoms and Cognitive Impairments in Schizophrenia: Two Key Symptoms Negatively Influencing Social Functioning.
  • K. Kaneko
  • Psychology, Medicine
    Yonago acta medica
  • 2018
TLDR
Using functional neuroimaging techniques, the size of these therapy-induced beneficial changes in neurocognitive performance has been demonstrated to be correlated with the degree of the changes in brain activation during performing some cognitive tasks in the prefrontal and temporal cortices, which suggests neurobiological effects are exerted by psychosocial cognitive remediation treatments.
Clinical management of negative symptoms of schizophrenia: An update.
EPA guidance on assessment of negative symptoms in schizophrenia
TLDR
This European Psychiatric Association (EPA) guidance recommends the use of persistent negative symptoms (PNS) construct in the context of clinical trials and highlights the need for further efforts to make the definition of PNS consistent across studies in order to exclude as much as possible secondary negative symptoms.
Measuring negative symptom change in schizophrenia: considering alternatives to self-report
TLDR
The purpose of this article is to highlight the limitations in current assessment measures for negative symptoms and discuss the advantages of quantitative objective measurement, particularly in the context of clinical trial research.
Psychometric evaluation of the negative syndrome of schizophrenia
TLDR
Current instruments for assessing the negative syndrome of schizophrenia were classified into two categories according to their content validity and assessment approach as first- or second-generation instruments, with the NSA being considered a transitional instrument between the two.
Correspondence between negative symptoms and potential sources of secondary negative symptoms over time
TLDR
The unambiguous interpretation between primary and secondary negative symptoms may lead to refined treatment approaches for schizophrenia and to increased effects of the interventions.
...
...

References

SHOWING 1-10 OF 32 REFERENCES
The positive and negative syndrome scale (PANSS) for schizophrenia.
TLDR
Review of five studies involving the PANSS provided evidence of its criterion-related validity with antecedent, genealogical, and concurrent measures, its predictive validity, its drug sensitivity, and its utility for both typological and dimensional assessment.
The NIMH-MATRICS consensus statement on negative symptoms.
TLDR
A consensus development conference was held to review the data relating to the existence of separate domains within negative symptoms, as a prerequisite for choosing appropriate measures of these domains in clinical trials and to examine issues that may interfere with treatment development.
Negative symptoms in schizophrenia. Definition and reliability.
  • N. Andreasen
  • Psychology, Medicine
    Archives of general psychiatry
  • 1982
TLDR
The developed Scale for the Assessment of Negative Symptoms has excellent interrater reliability and the five symptom complexes defined by the scale have good internal consistency, which indicates that the conceptual organization of the scale is also cohesive.
The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations
  • N. Andreasen
  • Psychology, Medicine
    British Journal of Psychiatry
  • 1989
TLDR
The SANS is complemented by a Scale for the Assessment of Positive Symptoms (SAPS), which permits detailed evaluation and global ratings of hallucinations, delusions, positive formal thought disorder and bizarre behaviour and taken together, the two scales provide a comprehensive set of rating scales.
The structure of negative symptoms within schizophrenia: implications for assessment.
TLDR
Findings suggest that this construct is multidimensional with at least 2 factors (involving diminished expression and anhedonia-asociality) and the importance of employing assessments that provide adequate coverage of the broad domain of negative symptoms.
The 4-Item Negative Symptom Assessment (NSA-4) Instrument: A Simple Tool for Evaluating Negative Symptoms in Schizophrenia Following Brief Training.
TLDR
Findings suggest that clinicians from a variety of geographic practices can, after brief training, use the 4-item Negative Symptom Assessment effectively to rapidly assess negative symptoms in patients with schizophrenia.
The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation.
TLDR
The CAINS is an empirically developed and evaluated measure of negative symptoms that is brief yet comprehensive and employable across a wide range of research and clinical contexts.
...
...